Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EDIT Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 3–5 Matrix Metrics)

EDIT Overall Winner 6-Pillar Tally: NTLA 0 – 6 EDIT Matrix Metrics: NTLA 5 – 3 EDIT

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas EDIT carries 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs EDIT
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
EDIT NASDAQ Head-to-Head Winner
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (NTLA 0 – 6 EDIT)

Columns: Metric · NTLA · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) -48.0% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $50M
Market Cap $1.5B $336.5M
3. Profitability & Quality EDIT
Gross Margin N/A -73.3%
Operating Margin -826.0% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -62.6% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$358M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 95.8% (38th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (5) vs EDIT (3)
Institutional Metric NTLA EDIT Criterion Row Edge
Market Capitalization
Scale
$1.5B $336.5M Larger Scale NTLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-826.0% -167.0% Higher Margin EDIT
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin NTLA
Return on Equity (ROE)
Capital Efficiency
-62.6% -147.4% Higher ROE NTLA
52-Week Range Position
Momentum
20% ($8–$18) 11% ($2–$4) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 2.32β · 102% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$53M $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +6.51 pp
NTLA: -12.43% · EDIT: -18.94%
3M Horizon NTLA +20.06 pp
NTLA: -13.79% · EDIT: -33.85%
6M Horizon NTLA +3.5 pp
NTLA: -21.2% · EDIT: -24.7%
1Y Horizon NTLA +40.34 pp
NTLA: +15.34% · EDIT: -25.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue EDIT Revenue NTLA Op. Margin EDIT Op. Margin Margin Leader
FY2018 $30M $30M -298.6% -356.1% NTLA
FY2019 $40M $20M -246.8% -686.4% NTLA
FY2020 $60M $90M -235.5% -148.6% EDIT
FY2021 $30M $30M -810.4% -756.1% EDIT
FY2022 $50M $20M -879.0% -1146.3% NTLA
FY2023 $40M $80M -1420.5% -216.6% EDIT
FY2024 $60M $30M -923.1% -777.2% EDIT
FY2025 $70M $40M -651.7% -394.9% EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ NTLA vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas EDIT carries 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.